Sunday, October 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Curis Inc Reports Mixed Financial Results for Fourth Quarter

Elaine Mendonca by Elaine Mendonca
February 8, 2024
in Breaking News
0
0
SHARES
53
VIEWS
Share on FacebookShare on Twitter

On February 8, 2024, Curis Inc. (CRIS) disclosed its financial results for the fourth quarter, revealing a net loss of $11.7 million. This translates to a loss of approximately $2.03 per share, taking into account the number of shares outstanding. Surpassing the analyst consensus estimate of $(2.11) by 3.79 percent, Curis Inc. managed to outperform expectations in terms of earnings per share.

However, the company’s quarterly sales fell short of projections. With reported sales amounting to $2.70 million, Curis Inc. missed the analyst consensus estimate of $3.02 million by 10.73 percent. Despite this setback, the company remains optimistic about its future prospects.

Looking at the bigger picture, Curis Inc. reported a loss of $47.4 million, or $8.96 per share, for the entire year. On a positive note, the company generated annual revenue of $10 million. As Curis Inc. reflects on its financial performance in 2023, it aims to strategize and implement measures to improve profitability in the coming year.

CRIS Stock Performance on February 8, 2024: Promising Rise Followed by After-Hours Setback

CRIS Stock Performance on February 8, 2024:

According to data sourced from CNN Money, CRIS was trading in the middle of its 52-week range and below its 200-day simple moving average. This indicates that the stock’s performance has been relatively stable, but it has not been able to gain enough momentum to surpass its long-term moving average.

One of the key highlights of CRIS’s performance on February 8, 2024, was its price change. The shares of CRIS experienced a notable increase of $1.26 since the market last closed, representing a rise of 13.42%.

However, despite the initial rise, CRIS faced a setback in after-hours trading. The stock dropped by $0.79, eroding a significant portion of its gains achieved during regular trading hours.

Closing at $10.65, CRIS’s performance on February 8, 2024, can be seen as a mixed bag. While the initial price surge of 13.42% was promising, the subsequent drop in after-hours trading dampened the overall performance of the stock.

Investors might have been disappointed by the reversal in momentum, causing them to sell off their holdings and resulting in the decline in value.

It is important to note that stock performance can be influenced by various factors, including market conditions, company news, and investor sentiment. Therefore, it is crucial for investors to consider these factors and conduct thorough research before making any investment decisions.

In conclusion, CRIS’s stock performance on February 8, 2024, showcased both positive and negative aspects. While the initial rise of 13.42% indicated a promising start, the subsequent drop in after-hours trading dampened the overall performance. Investors should closely monitor CRIS and keep an eye on any developments that might impact its future performance.

CRIS Stock Performance: Mixed Results on February 8, 2024

On February 8, 2024, CRIS stock experienced a mixed performance, with some key financial indicators showing improvement while others continued to decline. Let’s dive into the details of CRIS’s financial performance based on the data sourced from CNN Money.

Total revenue for CRIS in the last year amounted to $10.16 million, marking a decrease of 4.57% compared to the previous year. However, there was a significant increase of 28.95% in total revenue since the last quarter, with the company generating $2.83 million.

Moving on to net income, CRIS reported a net loss of -$56.67 million in the last year, representing a decrease of 24.73% compared to the previous year. However, there was a slight improvement in net income since the last quarter, with a net loss of -$12.18 million, reflecting a 1.84% increase.

Earnings per share (EPS) is another crucial metric to assess a company’s financial performance. CRIS reported an EPS of -$12.14 for the last year, witnessing a decline of 22.3% compared to the previous year. However, there was a positive development in EPS since the last quarter, with a value of -$2.13, representing an increase of 13.94%.

Overall, CRIS’s stock performance on February 8, 2024, exhibited a mixture of positive and negative results. While total revenue experienced a significant increase since the last quarter, it declined when compared to the previous year. Similarly, net income showed a slight improvement since the last quarter but remained in negative territory. On the other hand, EPS saw an increase since the last quarter, although it declined when compared to the previous year.

Investors should consider these financial indicators while evaluating CRIS as an investment opportunity. It is important to note that these figures provide only a snapshot of the company’s performance on a specific date and further analysis is required to fully understand the company’s financial health and potential for growth.

Tags: CRIS
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Alternative Energy Markets and money

Peabody Energys Fourth Quarter Earnings Report and Future Outlook

Finance_Fiscal (3)

Analyst Ratings and Price Targets for OneMain Holdings

Biotechnology Stock Exchange

Tenaya Therapeutics Announces Pricing Details for Underwritten Offering

Recommended

aTyr Pharma Stock

aTyr Pharma Shares Plummet Following Clinical Trial Failure

1 year ago
Finance_Banking (2)

Ally Financial Appoints Douglas Timmerman as Interim CEO Begins Search for Permanent Leader

3 years ago
LILAK stock news

Strs Ohio Reduces Stake in Liberty Latin America, Reflecting Investment Trends in the Telecommunications Sector

3 years ago
Netflix Stock

Netflix Enters High-Stakes Bidding War for Warner Bros. Discovery

11 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

The AI Rally Needs Cheap Money, and Cheap Money Is Scarce

Most Stocks Rose While the Index Fell: Earnings Week Is the Test

Tesla Jumps on a Roadster as Tech Slips Into the Weekend

CoreWeave’s Bonds Flash Red as Strong Earnings Fall Flat

Hot Core CPI Sorts the Stocks: ASML Delivers, J&J Stumbles

Goldman Delivers as Memory Stocks Slide Ahead of CPI

Trending

Alphabet Stock
Newsletter

Cloud Giants Face a Cash Test as Money Rotates to Safety

by Stephanie Dugan
October 24, 2026
0

Dear readers, The chip earnings are behind us, and the spotlight now moves to the companies that...

Bitcoin Stock

Lam, Tesla and Meta Clear the Bar and Still Get Sold

October 22, 2026
Danaher Stock

Beat Estimates, Lose Ground: Guidance Now Drives Earnings Season

October 21, 2026
Mastercard Stock

The AI Rally Needs Cheap Money, and Cheap Money Is Scarce

October 20, 2026
Meta Stock

Most Stocks Rose While the Index Fell: Earnings Week Is the Test

October 18, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cloud Giants Face a Cash Test as Money Rotates to Safety
  • Lam, Tesla and Meta Clear the Bar and Still Get Sold
  • Beat Estimates, Lose Ground: Guidance Now Drives Earnings Season

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com